Sept 15 (Reuters) - Japanese pharma company Takeda Pharmaceutical Co said on Wednesday the U.S. Food and Drug Administration has granted an accelerated approval to its drug, Exkivity, to treat a type of lung cancer. (Reporting by Dania Nadeem in Bengaluru; Editing by Shailesh Kuber)
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4,167 JPY | +0.90% | +1.56% | +2.76% |
05-16 | Takeda Canada Completes LOI Stage for Post-Transplant Cytomegalovirus Treatment | MT |
05-15 | Takeda Pharmaceutical's Dengue Vaccine Granted WHO Prequalification | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.76% | 41.69B | |
+32.09% | 693B | |
+29.39% | 584B | |
-1.34% | 372B | |
+20.34% | 332B | |
+7.39% | 294B | |
+14.25% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+8.49% | 168B |
- Stock Market
- Equities
- 4502 Stock
- News Takeda Pharmaceutical Company Limited
- Takeda Pharmaceutical : U.S. FDA approves Takeda's lung cancer therapy